Peer-Reviewed University Trial Finds NOVOS Core Improved Three Key Measures of Cardiovascular Health in Healthy Adults

Published in the European Heart Journal Open, the University of Surrey study gives longevity science early human evidence that supporting the biology of aging improves the systems that depend on it

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Longevity has become one of the fastest-growing categories in health and wellness, and the products have multiplied faster than the evidence behind them. Today NOVOS, a longevity-focused biotechnology company developing science-backed interventions for healthy aging, raises the standard for that evidence with the publication of the STAMINA trial in the European Heart Journal Open. The randomized, double-blind, placebo-controlled study was led by Professor Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey. It found that six months of daily NOVOS Core improved blood vessel function, arterial flexibility and systolic blood pressure in healthy adults aged 40 and older — people whose measures already sat within normal ranges, where change is hardest to show.

Aging is the leading risk factor for most chronic conditions that appear later in life, and the field of geroscience has shown that the pace of biological aging can change through lifestyle interventions. Showing that change in people requires measures that shift early and reflect health across the whole body. Blood vessels meet both tests. They show signs of aging years before symptoms appear, and their condition affects every organ they supply, which makes vascular health one of the clearest places to measure whether supporting the biology of aging helps people maintain their health earlier in life.

What the study found

After six months, participants taking NOVOS Core improved compared with placebo on three of the trial's vascular endpoints:

• Blood vessel function. Flow-mediated dilation (FMD), the trial's primary endpoint and an established measure of how well arteries widen as blood flow increases, increased by 47% from baseline in the NOVOS Core group. The adjusted improvement versus placebo was 2.9 percentage points, a magnitude considered clinically meaningful in published vascular research.
• Arterial flexibility. Carotid-femoral pulse wave velocity (PWV), the standard measure of arterial stiffness and a marker of vascular aging, fell with NOVOS Core and rose with placebo, an adjusted between-group difference of 1.18 meters per second. Pulse wave velocity typically rises by approximately 1.0 meter per second per decade across adulthood, and a difference of this size is commonly associated in the literature with multi-year differences in vascular aging.
• Blood pressure. Systolic blood pressure fell further with NOVOS Core than with placebo over six months, an adjusted difference of 6.1 mmHg. Participants' average blood pressure was within the normal range at the start of the trial. Systolic pressure typically rises with age as arteries stiffen; in this trial, it fell to a healthier level.

Blood vessel function improved within an hour of the first serving, and the gains held. One hour after the first serving, blood vessel function was already an adjusted 3.9 percentage points above placebo. The six-month measurements were taken in a fasted state, roughly 24 hours after each participant's last serving. In the NOVOS Core group, participants who started with the weakest blood vessel function and the highest blood pressure tended to improve the most. Cholesterol and other blood lipids stayed the same, suggesting the changes were not explained by lipid lowering.

A trial built to a clinical standard

Few supplement companies run human clinical trials, and fewer submit them to independent peer review. Professor Heiss, an internationally recognized expert in measuring endothelial function, ran STAMINA with colleagues at Royal Surrey NHS Foundation Trust. The trial enrolled 61 apparently healthy, non-smoking adults aged 40 and older: 33 took NOVOS Core and 28 took a placebo matched for look and taste. People with unstable cardiovascular disease, heart rhythm disorders or active cancer were excluded. 31 of the 61 participants were women. That's just over half the trial, while women made up about 41% of participants across more than 1,000 cardiovascular trials registered from 2017 to 2023, according to a Cedars-Sinai analysis in JAMA Network Open.

The choice of healthy volunteers raised the bar further. Their measures already sat at normal ranges, which leaves little room to improve and makes a measurable change harder to achieve.

The investigator-initiated trial was conducted by the University of Surrey and is registered as NCT06145087. NOVOS supported the study by providing the supplement, the matching placebo and an unrestricted contribution toward research costs. NOVOS had no role in study design, collection or primary interpretation of the data, or the decision to publish. The University of Surrey researchers retained control of the study data.

Designed around the biology of aging

NOVOS Core combines 12 natural ingredients in one daily drink mix. Each ingredient was selected for evidence that it acts on several of the 12 biological hallmarks of aging, for links to longevity in scientific studies and for decades of safe human use. NOVOS designed the formula to target the hallmarks of aging together, with the goal of supporting healthspan, lifespan and whole-body health, so its benefits would reach every organ system the aging process affects. Three independent measures of vascular health improved, which gives geroscience early human evidence for the field's central idea: support the biology of aging, and the systems downstream of it respond. The trial builds on earlier NOVOS laboratory and animal research and extends that work into people.

"I founded NOVOS to answer one question: what can a person do to slow the aging process and stay healthier for longer?" said Chris Mirabile, founder and CEO of NOVOS. "A credible answer demands the scrutiny medicine applies to anything it takes seriously, which means a blinded, placebo-controlled trial run by university researchers and reviewed by their peers. People deserve that level of proof from every company that puts the word 'longevity' on a label, and we intend to keep meeting it."

"Our hypothesis in this study was whether a multi-component supplement addresses many biological and biochemical processes related to vascular aging and has an effect on measures of vascular health. We found favourable changes in endothelial function, arterial stiffness and systolic blood pressure after six months," said Professor Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey and lead investigator of the STAMINA trial. "These findings are encouraging, and supplements can be a part of a healthy lifestyle."

"The cardiovascular system supplies every cell and organ in the body, it is one of the first systems to show signs of aging, and cardiovascular disease is the leading cause of death for men and women in the United States and worldwide," said Diogo Barardo, PhD, Director of R&D at NOVOS and a geroscientist - a scientist specialized in the biology of aging. "That made it the natural place to test our hypothesis that targeting the hallmarks of aging would improve cardiovascular health. The STAMINA results indicate it did, and in healthy adults, whose measures already sit close to normal and are among the hardest to move."

What comes next

STAMINA studied the vascular system first because blood vessels supply every organ in the body, and the results open the next phase of research. NOVOS is evaluating follow-up studies of NOVOS Core in other organ systems, including muscle function, brain and cognition, and skin, along with further analysis of its effects on the biological aging process itself.

The full study is available at https://novoslabs.com/study. Press materials, including key figures, the graphical abstract, and investigator and product images, are available at https://novoslabs.com/press/. 

About the STAMINA trial

STAMINA (Effects of a Supplement to Target Ageing Mechanisms on Vascular Function) was a single-center, randomized, double-blind, placebo-controlled trial conducted at the University of Surrey with Royal Surrey NHS Foundation Trust and published in the European Heart Journal Open. Healthy adults aged 40 and older took one 15-gram daily serving of NOVOS Core or a placebo for six months. The primary endpoint was change in flow-mediated dilation, and secondary endpoints included pulse wave velocity and systolic blood pressure.

About NOVOS

Founded in 2019, NOVOS is a longevity-focused biotechnology company developing evidence-based interventions to support healthy aging. Its products and digital tools are designed around the 12 biological hallmarks of aging and are supported by mechanistic research, preclinical studies, and human clinical trials. NOVOS operates as a Public Benefit Corporation and supports nonprofit and academic research organizations advancing the science of aging. To learn more, visit www.novoslabs.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Media Contact
Sofia Spieler
315-395-1877
sofia@novoslabs.com 

SOURCE NOVOS Labs